Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 15/20 | 0.72 |
| ▸ | PRKCH | P24723 | 14/20 | 0.72 |
| ▸ | PRKCD | Q05655 | 14/20 | 0.72 |
| ▸ | PRKCA | P17252 | 14/20 | 0.72 |
| ▸ | PRKCE | Q02156 | 12/20 | 0.72 |
| ▸ | PRKCB | P05771 | 12/20 | 0.72 |
| ▸ | JAK3 | P52333 | 7/20 | 0.64 |
| ▸ | JAK1 | P23458 | 6/20 | 0.64 |
| ▸ | GSK3B | P49841 | 2/20 | 0.64 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.64 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.64 |
| ▸ | PRKCG | P05129 | 1/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
| ▸ | CDK1 | P06493 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906489 | 0.85 | JAK3 (0.82) | PRKCQPRKCHPRKCDPRKCAPRKCE | |
| SCHEMBL4380148 | 0.84 | PRKCH (1.00) | PRKCQPRKCHPRKCDPRKCAPRKCE | |
| SCHEMBL990717 | 0.83 | PRKCA (0.66) | PRKCQPRKCHPRKCDPRKCAPRKCE | |
| SCHEMBL21583796 | 0.82 | JAK3 (0.81) | PRKCQPRKCHPRKCDPRKCAPRKCE | |
| SCHEMBL5460152 | 0.78 | PRKCA (0.68) | PRKCQPRKCHPRKCDPRKCAPRKCE | |
| Sotrastaurin SCHEMBL29364923 | 0.78 | PRKCH (1.00) | PRKCQPRKCHPRKCDPRKCAPRKCE | |
| Sotrastaurin SCHEMBL2500835 | 0.78 | PRKCH (1.00) | PRKCQPRKCHPRKCDPRKCAPRKCE | |
| Sotrastaurin SCHEMBL29526075 | 0.78 | PRKCH (1.00) | PRKCQPRKCHPRKCDPRKCAPRKCE | |
| SCHEMBL4377883 | 0.78 | PRKCH (1.00) | PRKCQPRKCHPRKCDPRKCAPRKCE | |
| SCHEMBL989017 | 0.76 | PRKCA (0.66) | PRKCQPRKCHPRKCDPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820672-B2 | 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases; | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | claimed |
| EP-2075249-B1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-7820672-B2 | 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases; | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| US-7820672-B2 | 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases; | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| EP-1597250-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| EP-1597250-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| JP-2009280592-A | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG | 2009-12-03 | — | — | JP | disclosed |
| EP-2075249-A2 | Indolylmaleimide derivatives | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-2075249-A2 | Indolylmaleimide derivatives | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2004072062-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |